Browse the evidence

LY3537021 was well tolerated with infrequent gastrointestinal adverse events.

LY3537021 may be a safe option for patients with T2D.

GLP-1 receptor agonists (GLP-1RAs) may help manage psoriasis (PsO) and psoriatic arthritis (PsA) in patients with obesity.

Clinicians may consider GLP-1RAs as a treatment option for obese patients with PsO and PsA.

Retatrutide (LY3437943) is a novel triple agonist that targets GLP-1, GIP, and glucagon receptors, representing a transformative advance in obesity pharmacotherapy.

Retatrutide may be considered as a new treatment option for obesity.

Retatrutide shows additional benefits for metabolic comorbidities such as NASH and cardiovascular disease.

Retatrutide may help manage obesity-related metabolic conditions.

Adipocyte browning enhances energy expenditure, improves insulin sensitivity, and mitigates lipid accumulation.

Adipocyte browning could be targeted in therapies for obesity and metabolic diseases.

The degree of muscle-based losses varied widely among the incretin groups.

Individual responses to incretin therapies can vary, necessitating personalized treatment approaches.

Glucagon-like peptide-1 receptor agonists may encourage a more holistic approach to treatment of CKM syndrome.

Clinicians should consider using GLP-1 receptor agonists for integrated treatment strategies.

Higher percentage body fat (PBF) is associated with successful weight reduction in both male (OR = 3.990) and female (OR = 2.266) patients.

Monitoring body fat percentage may help predict weight loss success in patients undergoing GLP-1RA treatment.

Bariatric surgery is associated with a 42.4% reduction in fat mass (FM) at 6 months, 49.7% at 12 months, and 49.7% at 24 months.

Bariatric surgery significantly reduces fat mass in patients over a 24-month period.

Both bariatric surgery and GLP-1RA treatment improve the fat-free mass (FFM) to fat mass (FM) ratio.

Both interventions are effective in improving body composition ratios.

The efficacy of GLP-1 receptor agonists was consistent across other important subpopulations.

GLP-1 receptor agonists can be considered effective for weight loss across diverse patient groups.

No significant adverse events were recorded during the study.

The combination appears to be safe for use in the studied population.

Traditional interventions related to diet and exercise have fallen short in addressing obesity.

New treatment approaches may be necessary to effectively manage obesity.

New treatment approaches, including glucagon-like peptide-1 agonists, may be effective for weight loss in pregnant individuals.

Healthcare providers should consider new medical therapies for managing obesity in pregnant individuals.

Patients show a strong commitment to obtaining and maintaining weight-loss medication despite disruptions to their daily lives.

Health care providers should recognize the dedication of patients in managing their weight-loss treatment.

Health care professionals align patients' expectations for immediate weight loss while navigating moral reasoning about weight loss methods.

Practitioners should be aware of the expectations patients have and the ethical considerations in weight-loss discussions.

Insulin therapy often leads to fat mass accumulation and increases the risk of sarcopenic obesity.

Practitioners should be cautious of insulin therapy's potential to increase fat mass and risk of sarcopenic obesity.

The FDA has conditionally approved Resmetirom as the first pharmacological treatment for MASH.

Clinicians should consider Resmetirom as a treatment option for MASH.

Glucagon-like peptide-1 (GLP-1) receptor agonists are widely prescribed for the treatment of type 2 diabetes and obesity.

Practitioners should consider GLP-1 receptor agonists for managing type 2 diabetes and obesity.

GLP-1 agonists can modulate appetite through effects on the hypothalamus, making them promising for obesity treatment.

GLP-1 agonists may be effective options for patients looking to manage obesity through appetite control.

A statistically lower proportion of patients in the compounded Semaglutide group (71.61%) reported at least one side effect compared to the pure Semaglutide group (77.40%).

Practitioners may consider that compounded Semaglutide is associated with a lower incidence of side effects.

The proposed nanocomplex is a promising system for long-acting injectable delivery of semaglutide, potentially enhancing patient compliance.

This delivery system may improve treatment adherence in patients requiring semaglutide.

GLP-1 RA initiation was associated with a reduced incidence rate of alcohol use disorders (AUD) post RYGB (1.1% vs. 1.8%) with a hazard ratio of 0.77.

Practitioners may consider GLP-1 RAs as a strategy to reduce AUD in patients post RYGB.

Bariatric medicine includes a range of medical and surgical interventions to address obesity.

Practitioners should consider a variety of interventions when managing obesity.